Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Non Operating Income (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Non Operating Income for 17 consecutive years, with $5.5 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income rose 5600.0% to $5.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.6 million through Dec 2025, up 4700.0% year-over-year, with the annual reading at $800000.0 for FY2025, N/A changed from the prior year.
  • Non Operating Income for Q4 2025 was $5.5 million at Myriad Genetics, up from $400000.0 in the prior quarter.
  • The five-year high for Non Operating Income was $119.7 million in Q3 2021, with the low at -$5.9 million in Q4 2021.
  • Average Non Operating Income over 5 years is $6.8 million, with a median of -$100000.0 recorded in 2022.
  • The sharpest move saw Non Operating Income skyrocketed 7581.25% in 2021, then plummeted 2300.0% in 2023.
  • Over 5 years, Non Operating Income stood at -$5.9 million in 2021, then skyrocketed by 111.86% to $700000.0 in 2022, then tumbled by 257.14% to -$1.1 million in 2023, then surged by 90.91% to -$100000.0 in 2024, then skyrocketed by 5600.0% to $5.5 million in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at $5.5 million, $400000.0, and -$1.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.